Our top pick for
Moderna’s two-dose COVID-19 vaccine commanded public attention with the announcement of its 94.5% efficacy rate. But this vaccine has yet to be approved by the FDA and may not be available to the general public for months. Here’s how to buy Moderna stock.
On November 16, Moderna released a statement based on late-stage trial data of its two-dose coronavirus vaccine it’s developing with the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases. It claims the vaccine is 94.5% effective in preventing COVID-19. This announcement arrived just one week behind vaccine competitor Pfizer’s 90% efficacy rate statement.
Moderna’s data comes from a study of 30,000 volunteers and was released as a news statement — not in a peer-reviewed journal. This vaccine data is promising but far from conclusive. There’s still room for Moderna’s protection rate to change by the time it finishes its study.
Moderna is working towards emergency-use approval with the US Food and Drug Administration (FDA). The FDA requires coronavirus vaccines to hold an efficacy rate of at least 50% to be approved.
In response to Moderna’s announcement, its stock spiked by over 8%, the Dow Jones Industrial Average rose by nearly 400 points and the S&P 500 set a record high above 3,615 points.
Both Moderna and Pfizer have made numerous news headlines as they work to develop effective coronavirus vaccines. But how do their vaccines compare? Here’s how these COVID-19 vaccines stack up.
|Type of vaccine||Messenger RNA (mRNA)||Messenger RNA (mRNA|
|Trial size||30,000 people||43,538 people|
|Number of doses||2 shots, 28 days apart||2 shots, 21 days apart|
|Production||Up to 20 million doses by the end of 2020||Up to 50 million doses by the end of 2020|
|Years in business||10||171|
|Number of manufactured drugs||0||300+|
Since the stock market crash in March caused by coronavirus, Moderna's share price has had significant positive movement.
Its last market close was USD$73.94, which is 75.34% up on its pre-crash value of USD$18.23 and 312.84% up on the lowest point reached during the March crash when the shares fell as low as USD$17.91.
If you had bought USD$1,000 worth of Moderna shares at the start of February 2020, those shares would have been worth USD$1,303.79 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$3,628.24.
|Latest market close||USD$73.94|
|52-week range||USD$17.68 - USD$109.29|
|50-day moving average||USD$77.7708|
|200-day moving average||USD$70.1764|
|Wall St. target price||USD$106.13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.348|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-19)||-20.30%|
|1 month (2020-10-26)||5.27%|
|3 months (2020-08-26)||4.88%|
|6 months (2020-05-26)||28.12%|
|1 year (2019-11-26)||263.70%|
|2 years (2018-11-22)||N/A|
|3 years (2017-11-22)||N/A|
|5 years (2015-11-22)||N/A|
|Revenue TTM||USD$246.7 million|
|Gross profit TTM||USD$-436,100,000|
|Return on assets TTM||-12.37%|
|Return on equity TTM||-29.81%|
|Market capitalisation||USD$43.2 billion|
TTM: trailing 12 months
There are currently 25.2 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 7.7% down from 27.3 million last month.
There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.
Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 8.6 million). Moderna's SIR currently stands at 2.95. In other words for every 100,000 Moderna shares traded daily on the market, roughly 2950 shares are currently held short.
However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 60 shares are currently held short) or 0.0812% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 81 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.
Find out more about how you can short Moderna stock.
We're not expecting Moderna to pay a dividend over the next 12 months.
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing SELF, with 24-hour and historical pricing before you buy.
Steps to owning and managing GLP, with 24-hour and historical pricing before you buy.
Steps to owning and managing FRGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXFO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ESRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLOW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FOF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing CGNX, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.